239 related articles for article (PubMed ID: 30730407)
1. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
[TBL] [Abstract][Full Text] [Related]
3. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
[TBL] [Abstract][Full Text] [Related]
4. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
[TBL] [Abstract][Full Text] [Related]
5. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
Kijima T; Yamamoto H; Saito K; Kusuhara S; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Sakai Y; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Cancer Immunol Immunother; 2021 Mar; 70(3):657-665. PubMed ID: 32876736
[TBL] [Abstract][Full Text] [Related]
6. Targeting advanced urothelial carcinoma-developing strategies.
Alhalabi O; Rafei H; Shah A; Siefker-Radtke A; Campbell M; Gao J
Curr Opin Oncol; 2019 May; 31(3):207-215. PubMed ID: 30844889
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
Fujiwara Y; Karol AB; Joshi H; Reford E; Izadmehr S; Doroshow DB; Galsky MD
Crit Rev Oncol Hematol; 2024 May; 197():104352. PubMed ID: 38614269
[TBL] [Abstract][Full Text] [Related]
8. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
Eturi A; Bhasin A; Zarrabi KK; Tester WJ
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675715
[TBL] [Abstract][Full Text] [Related]
9. Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer.
van Wilpe S; Gorris MAJ; van der Woude LL; Sultan S; Koornstra RHT; van der Heijden AG; Gerritsen WR; Simons M; de Vries IJM; Mehra N
Front Immunol; 2021; 12():802877. PubMed ID: 35046958
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Pezzicoli G; Ciciriello F; Musci V; Minei S; Biasi A; Ragno A; Cafforio P; Rizzo M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674231
[TBL] [Abstract][Full Text] [Related]
11. Immune resilience in response to cancer therapy.
Gicobi JK; Barham W; Dong H
Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
[No Abstract] [Full Text] [Related]
12. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
Mock A; Zschäbitz S; Kirsten R; Scheffler M; Wolf B; Herold-Mende C; Kramer R; Busch E; Jenzer M; Jäger D; Grüllich C
Cancer Immunol Immunother; 2019 Dec; 68(12):2005-2014. PubMed ID: 31701161
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.
Gopalakrishnan D; Koshkin VS; Ornstein MC; Papatsoris A; Grivas P
Ther Clin Risk Manag; 2018; 14():1019-1040. PubMed ID: 29892196
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder.
van Wilpe S; Gerretsen ECF; van der Heijden AG; de Vries IJM; Gerritsen WR; Mehra N
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32967190
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of single cell sequencing for bladder cancer.
Yadollahvandmiandoab R; Jalalizadeh M; Dionato FAV; Buosi K; Leme PAF; Col LSBD; Giacomelli CF; Assis AD; Bashirichelkasari N; Reis LO
Oncol Res; 2024; 32(4):597-605. PubMed ID: 38560564
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics.
Dwivedi R; Jain A; Gupta S; Chandra S
Indian J Otolaryngol Head Neck Surg; 2024 Jun; 76(3):2257-2272. PubMed ID: 38883453
[TBL] [Abstract][Full Text] [Related]
17. Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Ariyawutyakorn W; Saichaemchan S; Varella-Garcia M
J Cancer; 2016; 7(6):633-49. PubMed ID: 27076844
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the impact of age on immune checkpoint therapy biomarkers.
Erbe R; Wang Z; Wu S; Xiu J; Zaidi N; La J; Tuck D; Fillmore N; Giraldo NA; Topper M; Baylin S; Lippman M; Isaacs C; Basho R; Serebriiskii I; Lenz HJ; Astsaturov I; Marshall J; Taverna J; Lee J; Jaffee EM; Roussos Torres ET; Weeraratna A; Easwaran H; Fertig EJ
Cell Rep; 2021 Nov; 37(7):110033. PubMed ID: 34788629
[No Abstract] [Full Text] [Related]
19. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T; Kockx M; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Szabados B; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; van Dam PJ; Stanoeva D; Daelemans S; Mariathasan S; Tea JS; Mousa K; Banchereau R; Castellano D
Nat Med; 2019 Nov; 25(11):1706-1714. PubMed ID: 31686036
[TBL] [Abstract][Full Text] [Related]
20. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Kamoun A; de Reyniès A; Allory Y; Sjödahl G; Robertson AG; Seiler R; Hoadley KA; Groeneveld CS; Al-Ahmadie H; Choi W; Castro MAA; Fontugne J; Eriksson P; Mo Q; Kardos J; Zlotta A; Hartmann A; Dinney CP; Bellmunt J; Powles T; Malats N; Chan KS; Kim WY; McConkey DJ; Black PC; Dyrskjøt L; Höglund M; Lerner SP; Real FX; Radvanyi F;
Eur Urol; 2020 Apr; 77(4):420-433. PubMed ID: 31563503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
